Core Insights - On January 13, 2026, Alibaba-W (09988), Tencent Holdings (00700), and Xiaomi Group-W (01810) were the top three companies by trading volume in the Southbound Stock Connect, with trading amounts of 81.05 billion, 29.45 billion, and 28.57 billion respectively [1] - The same companies also led in trading volume in the Shenzhen-Hong Kong Stock Connect, with trading amounts of 58.01 billion, 23.48 billion, and 21.05 billion respectively [1] Southbound Stock Connect (Shanghai-Hong Kong) - Alibaba-W (09988) had a trading amount of 81.05 billion and a net buy amount of -90.46 million [2] - Tencent Holdings (00700) recorded a trading amount of 29.45 billion with a net buy amount of +6.61 million [2] - Xiaomi Group-W (01810) achieved a trading amount of 28.57 billion and a net buy amount of +3.24 billion [2] - Other notable companies included Goldwind Technology (02208) with 23.07 billion and a net buy of +85.70 million, and SMIC (00981) with 22.72 billion and a net buy of -1.73 billion [2] Southbound Stock Connect (Shenzhen-Hong Kong) - Alibaba-W (09988) had a trading amount of 58.01 billion and a net buy amount of +1.16 billion [2] - Tencent Holdings (00700) recorded a trading amount of 23.48 billion with a net buy amount of +749 million [2] - Xiaomi Group-W (01810) achieved a trading amount of 21.05 billion and a net buy amount of +283 million [2] - Other significant companies included SMIC (00981) with 18.13 billion and a net buy of -661 million, and Kuaishou-W (01024) with 12.21 billion and a net buy of +114 million [2]

Market Overview - A-shares opened high but closed lower, with the Shanghai Composite Index down 0.64%, Shenzhen Component Index down 1.37%, and ChiNext Index down 1.96%. The total trading volume in the Shanghai and Shenzhen markets was approximately 3.70 trillion yuan, showing a slight increase compared to the previous trading day. More than 3,700 stocks declined [1] Industry Insights - The commercial aerospace sector saw significant activity, leading to a market pullback. However, this correction is considered normal after continuous gains, and the spring market trend is expected to continue. Investors are advised to focus on technology growth and related sectors such as commercial aerospace, AI applications, and new energy, while also considering cash flow/dividend assets to mitigate market volatility [1] - The medical services, precious metals, and GEO concept stocks were among the top gainers today, while commercial aerospace, semiconductors, and chemical fiber industries experienced the largest declines [1] Pharmaceutical Sector Highlights - The pharmaceutical sector led the market gains due to several key developments: 1. Rongchang Bio signed an exclusive licensing agreement with AbbVie for RC148, with a total transaction value of 5.6 billion USD, highlighting the significant market potential of the PD-1/VEGF dual antibody track [2] 2. WuXi AppTec, a leading CXO, announced its 2025 performance forecast, expecting annual revenue of 45.456 billion yuan, a year-on-year increase of 15.84%, exceeding expectations [2] 3. Tempus AI reported better-than-expected earnings, with diagnostic business revenue of 955 million USD, a year-on-year growth of 111%, indicating ongoing global advancements in AI medical technology [2] - The pharmaceutical sector's global competitiveness continues to strengthen, with ongoing international expansion and commercial profitability [2] Power Grid Sector Developments - The domestic power grid performed relatively well in the afternoon, driven by the demand for renewable energy consumption from large-scale wind and solar projects. The vast territory of China necessitates long-distance transportation, which is expected to further stimulate demand for UHV (Ultra High Voltage) construction. During the 14th Five-Year Plan period, UHV DC is expected to maintain an annual approval pace of 3 to 4 lines, while UHV AC is anticipated to approve an average of 2 large projects annually [2] - In North America, explosive growth in AIDC (Artificial Intelligence Data Center) is creating new electricity demand, and China's complete power grid industry chain, efficient delivery, and rich overseas experience position it as a key supplier to fill this gap [2]

Market Performance - The Hong Kong stock market saw a significant early rise but narrowed gains in the afternoon, with the Hang Seng Index closing at 26,848.47 points, up 239.99 points, or 0.90% [1] - The total trading volume for the day was 315.2 billion HKD, showing a slight increase compared to the previous day [1] Sector Highlights - Gold stocks continued their upward trend, with China Gold International (HK02099) rising over 7%, Lingbao Gold (HK03330) up nearly 3%, and Zijin Mining (HK01818) and Shandong Gold (HK01787) both increasing over 2% [3] - The Hang Seng Tech Index closed at 5,869.79 points, up 6.59 points, or 0.11% [4] Company News - Citigroup has aggressively raised its short-term outlook for precious metals, predicting gold prices could reach 5,000 USD/oz and silver 100 USD/oz within three months due to escalating geopolitical risks, physical shortages, and uncertainties in Federal Reserve policies [6] - Innovative drug concept stocks performed well, with WuXi AppTec (HK02359) rising over 8% [7] - WuXi AppTec announced an expected annual revenue of 45.456 billion CNY, a year-on-year increase of 15.84%, with adjusted net profit expected to rise by approximately 41.33% to 14.957 billion CNY [9] - Rongchang Biopharmaceutical (HK09995) signed an exclusive licensing agreement with AbbVie for its new dual-target PD-1/VEGF antibody drug RC148, receiving an upfront payment of 650 million USD and potential total payments of up to 5.6 billion USD [11] Market Outlook - Guosen Securities noted that the Hong Kong stock market has not yet fully strengthened, with traditional industries still dominating, and concerns over intensified competition among internet companies affecting market sentiment [13] - The pricing power of Hong Kong stocks is influenced by overseas risk appetite, and the appreciation of the RMB is being offset by profit-taking sentiment [13] - The AH premium index indicates that quality H-shares are preferred over A-shares, with domestic investors favoring leading companies through southbound channels [13]

格隆汇1月13日｜中信建投证券研报指出，荣昌生物与艾伯维就RC148（PD1/VEGF）实现全球合作，整 体交易的首付款为6.5亿美元，并有资格获得最高达49.5亿美元的开发、监管和商业化里程碑付款，同时 还拥有在大中华地区以外的净销售额的两位数分级特许权使用费，首付款和总金额超出市场预期。具体 来看，RC148此前在1L NSCLC和后线NSCLC中均展现出优异临床数据，药物目前在多个实体瘤中开展 临床研究，未来可期。认为本次合作让公司的国际化得到进一步加强，看好公司未来发展。预计2025- 2027年，公司收入分别为24.55亿元、33.88亿元和45.74亿元，维持"买入"评级。（暂不考虑BD的收入 确认影响） ...

Group 1 - The core point of the news is the significant licensing agreement between Rongchang Biopharma and AbbVie for the development and commercialization of RC148, a novel bispecific antibody targeting PD-1 and VEGF, which could lead to substantial financial benefits for Rongchang Biopharma [1] - Rongchang Biopharma will receive an upfront payment of $650 million and is eligible for up to $4.95 billion in milestone payments, along with double-digit royalties on net sales outside Greater China [1] - The deal exemplifies the "China innovation + global market" model in drug development, indicating a growing trend of collaboration between Chinese biotech firms and international pharmaceutical companies [1] Group 2 - In 2024, U.S. pharmaceutical companies significantly increased their acquisition of Chinese innovative drugs, with a year-on-year growth of 66%, leading to a total licensing transaction value of $41.5 billion [2] - Recently, five business development projects have been established in a short period, covering various fields such as small molecule inhibitors, monoclonal antibodies, bispecific antibodies, ADCs, and RDCs, indicating a flourishing environment for Chinese innovative drugs [2] - The Hong Kong innovation drug sector is showing signs of recovery, with the Hang Seng Innovation Drug Index having corrected approximately 25% since its peak in September 2025, but is now rebounding [3] Group 3 - The U.S. biotech sector, particularly the Nasdaq Biotechnology Index, has reached new highs, increasing by 23% since September of last year, highlighting a disparity in performance compared to the Hong Kong innovation drug sector [5] - The recent surge in business development projects serves as a catalyst that may reactivate the Hong Kong innovation drug sector, which is currently perceived to be at a relatively safe valuation compared to the Nasdaq [5]

Group 1 - The CRO and innovative drug sectors are experiencing strong gains, with stocks like Rongchang Biopharma A-shares and H-shares, WuXi AppTec, and Sanofi rising by 17%, 9%, 7.9%, and 7.2% respectively, leading to a 3.5% increase in the Tianhong Innovative Drug ETF [1] - The Tianhong Innovative Drug ETF (517380) is the only ETF tracking the Hang Seng Shanghai-Shenzhen Hong Kong Innovative Drug Selected 50 Index, focusing on 50 actively traded innovative drug and CXO companies with high R&D investment [1] - The ETF has seen a net inflow of 207 million yuan over the past five days, indicating strong investor interest [1] Group 2 - The 44th JPMorgan Global Healthcare Conference is set to take place, with over 20 domestic innovative drug companies confirmed to participate, including WuXi AppTec and several others [1] - WuXi AppTec is projected to achieve a profit of 19.151 billion yuan in 2025, representing a year-on-year increase of 103%, with Q4 net profit expected to reach 7.075 billion yuan, a quarter-on-quarter increase of 101% [1] - The sixth batch of national centralized procurement for high-value medical consumables is about to open for bidding, including 12 types of medical consumables [2] Group 3 - The medical device ETF (159873) has a significant focus on brain-machine interfaces, accounting for over 19% of its composition, indicating strong technological attributes [2] - The ETF's components include a high proportion of stocks from the Sci-Tech Innovation Board and the Growth Enterprise Market, nearly 80%, suggesting a robust growth potential [2] - The industry outlook for 2026 remains positive, with a focus on innovation, international expansion, and recovery in challenging markets, particularly in the CXO and upstream supply chain sectors [2]

数据宝统计，截至14:22，荣昌生物成交额21.94亿元，创上市以来新高。最新股价上涨19.66%，换手率 12.14%。上一交易日该股全天成交额为6.60亿元。（数据宝） （文章来源：证券时报网） ...

Core Viewpoint - Rongchang Biologics has signed an exclusive licensing agreement with AbbVie for its novel PD-1/VEGF bispecific antibody drug RC148, which is expected to enhance the immune system's anti-tumor activity by targeting both PD-1 and VEGF pathways [1][2] Group 1: Financial Aspects - Rongchang Biologics will receive an upfront payment of $650 million and may earn up to $4.95 billion in milestone payments based on the achievement of development, regulatory, and commercialization milestones [2] - The company will also receive a tiered royalty on net sales achieved by AbbVie outside of Greater China [2] - In the first three quarters of 2025, Rongchang Biologics reported total revenue of 1.72 billion yuan, a year-on-year increase of 42.27% [3] Group 2: Product and Development - RC148 is designed to activate anti-tumor immune responses while inhibiting tumor-driven angiogenesis, and is currently undergoing clinical studies for various advanced malignant solid tumors in China [1][3] - This collaboration marks another significant step in Rongchang Biologics' international strategy, following previous partnerships for its core products [3] Group 3: Strategic Implications - The partnership with AbbVie is seen as a crucial move for Rongchang Biologics to leverage international pharmaceutical resources for global product development [3] - AbbVie’s extensive experience in global clinical development and commercialization in oncology is expected to support the overseas launch of RC148 [3] - The cash flow generated from this deal will further bolster Rongchang Biologics' R&D funding, ensuring the development of its pipeline products [3]

Investment Rating - The investment rating for Rongchang Biologics (688331) is "Buy" (maintained) [2] Core Insights - On January 12, 2026, Rongchang Biologics announced an exclusive licensing agreement with AbbVie for its self-developed PD-1/VEGF bispecific antibody drug RC148. AbbVie will receive exclusive rights for development, production, and commercialization outside Greater China, with an upfront payment of $650 million and potential milestone payments up to $4.95 billion, along with double-digit royalties on net sales outside Greater China [5][11] - The deal is seen as a significant entry into the business development (BD) market for 2026, highlighting the growing trend of large licensing transactions in the PD-1/VEGF space, which is crucial for next-generation cancer immunotherapy [6] - AbbVie, a well-established player in oncology, aims to enhance treatment standards for patients with difficult-to-treat cancers, and the acquisition of RC148 will further strengthen its pipeline in immuno-oncology [7] Financial Projections - Revenue projections for Rongchang Biologics are adjusted to 2.25 billion, 7.42 billion, and 3.98 billion yuan for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 31.1%, 229.6%, and -46.3% [11] - The net profit attributable to the parent company is expected to be -763 million, 3.19 billion, and 220 million yuan for the same years, with growth rates of 48.0%, 517.8%, and -93.1% [11] - The gross margin is projected to remain stable, increasing from 80.4% in 2024 to 82.2% in 2027 [13]

上天天基金APP搜索777注册即可领500元券包，优选基金10元起投！限量发放！先到先得！ 昨天联手大涨的商业航天和AI应用板块，今天上午，两者走势"分道扬镳"。 商业航天板块大幅波动，在早盘的前7分钟，板块持续下跌，中国卫通、航天发展、航天机电等多 只人气股直线跌停。10:35之后，商业航天板块迎来修复，临近上午收盘，板块拉升，跌幅收窄。 AI应用继续上涨，其中，"AI+制药""AI+医疗"方向走势最强。迪安诊断、中文在线、天龙集团等个 股大涨。 此外，保险、油气开采、锂矿等板块上涨。截至上午收盘，上证指数下跌0.03%，深证成指下跌 0.31%，创业板指下跌0.83%。 医药股大涨 今天上午，医药股大涨，医疗服务、生物制品等板块涨幅居前。 | 成分股 星金 | 简况(F10) | 资金 | 板块分? | | --- | --- | --- | --- | | 名称代码 | 最新 | 涨幅 ◆ | 流通市值 | | 诺思格 | 76.48 | 20.01% | 43.7 Z | | 融 301333 | | | | | 首板涨停 最终涨停 10:07 | | | | | 涨博医药 | 56.64 | 20. ...